GeneFerm Biotechnology Co., Ltd. (TPEX:1796)
Taiwan · Delayed Price · Currency is TWD 29.65
-0.65 (-2.15%)
Aug 19, 2026, 1:24 PM CST
GeneFerm Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 664.94 | 677.1 | 521.16 | 793.77 | 633.96 | 522.33 | |
Revenue Growth | 7.05% | 29.92% | -34.34% | 25.21% | 21.37% | 41.82% |
Cost of Revenue | 494 | 486.3 | 424.42 | 507.42 | 411.8 | 329.68 |
Gross Profit | 170.94 | 190.8 | 96.75 | 286.35 | 222.16 | 192.65 |
Selling, General & Admin | 116.12 | 111.22 | 102.93 | 104.88 | 96.71 | 88.82 |
Research & Development | 33.86 | 33.54 | 29.31 | 28.33 | 24.18 | 23.56 |
Operating Expenses | 151.2 | 144.72 | 131.15 | 132.79 | 120.17 | 113.82 |
Operating Income | 19.74 | 46.08 | -34.41 | 153.57 | 101.99 | 78.84 |
Interest Expense | -6.2 | -6.22 | -4.44 | -4.17 | -3.82 | -7.32 |
Interest & Investment Income | 2.38 | 1.82 | 1.54 | 0.92 | 0.33 | 0.21 |
Currency Exchange Gain (Loss) | 2.21 | -9.11 | 4.8 | 0.84 | 9.66 | -2.67 |
Other Non Operating Income (Expenses) | 2.8 | 2.42 | 5.03 | 2.27 | 2.6 | 1.51 |
EBT Excluding Unusual Items | 20.93 | 34.98 | -27.49 | 153.42 | 110.76 | 70.57 |
Gain (Loss) on Sale of Investments | - | - | - | - | -0.43 | - |
Gain (Loss) on Sale of Assets | 0.06 | -0.28 | 0.02 | 0.01 | -0.11 | 0.04 |
Other Unusual Items | - | - | - | - | - | -0.21 |
Pretax Income | 20.98 | 34.7 | -27.47 | 153.43 | 110.21 | 70.4 |
Income Tax Expense | 3.91 | 5.83 | -4.94 | 28.81 | 16.76 | 12.98 |
Net Income | 17.07 | 28.86 | -22.53 | 124.62 | 93.45 | 57.41 |
Net Income to Common | 17.07 | 28.86 | -22.53 | 124.62 | 93.45 | 57.41 |
Net Income Growth | - | - | - | 33.35% | 62.78% | 1167.67% |
Shares Outstanding (Basic) | 41 | 41 | 41 | 41 | 41 | 40 |
Shares Outstanding (Diluted) | 42 | 42 | 41 | 42 | 43 | 46 |
Shares Change | 0.10% | 0.11% | -0.36% | -2.26% | -8.00% | 65.83% |
EPS (Basic) | 0.41 | 0.70 | -0.54 | 3.01 | 2.26 | 1.45 |
EPS (Diluted) | 0.41 | 0.70 | -0.54 | 2.99 | 2.20 | 1.32 |
EPS Growth | - | - | - | 35.63% | 66.87% | 725.71% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 78.36 | 75.89 | -14.31 | 120.37 | -155.74 | -32.65 |
Free Cash Flow Per Share | 1.89 | 1.83 | -0.34 | 2.89 | -3.66 | -0.70 |
Dividend Per Share | 0.700 | 0.700 | - | 2.000 | 1.500 | 1.000 |
Dividend Growth | - | - | - | 33.33% | 50.00% | 1103.93% |
Gross Margin | 25.71% | 28.18% | 18.56% | 36.08% | 35.04% | 36.88% |
Operating Margin | 2.97% | 6.80% | -6.60% | 19.35% | 16.09% | 15.09% |
Profit Margin | 2.57% | 4.26% | -4.32% | 15.70% | 14.74% | 10.99% |
Free Cash Flow Margin | 11.78% | 11.21% | -2.74% | 15.17% | -24.57% | -6.25% |
EBITDA | 85.71 | 113.48 | 37.89 | 219.41 | 145.16 | 117.76 |
EBITDA Margin | 12.89% | 16.76% | 7.27% | 27.64% | 22.90% | 22.55% |
D&A For EBITDA | 65.97 | 67.41 | 72.3 | 65.84 | 43.16 | 38.92 |
EBIT | 19.74 | 46.08 | -34.41 | 153.57 | 101.99 | 78.84 |
EBIT Margin | 2.97% | 6.80% | -6.60% | 19.35% | 16.09% | 15.09% |
Effective Tax Rate | 18.63% | 16.81% | - | 18.78% | 15.21% | 18.44% |